IP Library › Granted Patent US 12,600,719
Granted Patent B2
US 12,600,719 · App. 18/019,527 · Granted Apr 14, 2026

Salt inducible kinase inhibitors

Inventors: Marc Nathan Wein (Wellesley, MA); William J. Greenlee (Teaneck, NJ)
Assignee: The General Hospital Corporation
C07D471/04C07D401/12C07D403/04C07D403/12C07D405/14C07D409/14C07D471/10C07D487/10C07D498/10C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,600,719
App. No.
18/019,527
Granted
Apr 14, 2026
Kind
B2
Abstract

The present application provides compounds that modulate the activity of one or more salt inducible kinases (SIKs). Pharmaceutical composition and methods of treating diseases associated with abnormal expression and/or activity of one or more SIKs are also provided.

Claims (104)

1 . A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

V, X, and Z are each C, and W and Y are each N; or

V, Y, and Z are each C, and W and X are each N; or

V and Y are each C, and W, X, and Z are each N;

U is CR 3 or N;

U′ is CR 5 or N;

U″ is CR 6 or N;

R 1 is selected from 5 membered heteroaryl, OR a1 , C(O)NR c1 R d1 , and NR c1 C(O)R b1 , wherein the 5 membered heteroaryl is optionally substituted with 1 or 2 independently selected R 1A substituents;

R a1 , R b1 , R c1 , and R d1 are each independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl, and (5-10 membered heteroaryl)-C 1-6 alkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl, and (5-10 membered heteroaryl)-C 1-6 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 1A substituents;

or R c1 and R d1 , together with the nitrogen to which they are attached, come together to form a 10-14 membered heterocycloalkyl or 10-14 membered heteroaryl group, wherein the 10-14 membered heterocycloalkyl and 10-14 membered heteroaryl group are each optionally substituted with 1, 2, 3, or 4 independently selected R 1A substituents;

each R 1A is independently selected from halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 6-10 aryl, C 3-10 cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, NO 2 , CN, wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl are each optionally substituted with C 1-4 alkoxy;

R 2 is selected from H, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, and C 1-6 alkoxy;

R 3 is selected from H, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, and C 1-6 alkoxy;

R 4 is selected from H, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl, (5-10 membered heteroaryl)-C 1-6 alkyl, NO 2 , CN, OR a4 , C(O)R b4 , C(O)NR c4 R d4 , C(O)N(R c4 )NR c4 R d4 , NR c4 C(O)R b4 , C(O)OR a4 , OC(O)R b4 , OC(O)NR c4 R d4 , and NR c4 C(O)OR a4 , wherein the C 6-10 aryl, C 3-10 cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl, and (5-10 membered heteroaryl)-C 1-6 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 4A substituents;

R a4 , R b4 , R c4 , and R d4 are each independently selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2 -6 alkynyl, C 1-6 haloalkyl, and C 1-6 alkoxy;

each R 4A is independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, and C 1-6 alkoxy;

R 5 is selected from H, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, and C 1-6 alkoxy;

or R 4 and R 5 , together with the carbon atoms to which they are attached, come together to form a 5-6 membered aryl ring which is optionally substituted with 1, 2, 3, or 4 independently selected R 7 substituents;

R 6 is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, and C 1-6 alkoxy;

each R 7 is independently selected from C 6-10 aryl, C 3-10 cycloalkyl, 4-14 membered heterocycloalkyl, 5-10 membered heteroaryl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl, (5-10 membered heteroaryl)-C 1-6 alkyl, NO 2 , CN, and OR a7 , wherein the C 6-10 aryl, C 3-10 cycloalkyl, 4-14 membered heterocycloalkyl, 5-10 membered heteroaryl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl, (5-10 membered heteroaryl)-C 1-6 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 7A substituents;

each R a7 is independently selected from C 6-10 aryl, C 3-10 cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl, and (5-10 membered heteroaryl)-C 1-6 alkyl; and each R 7A is independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl) amino, phenyl, C 3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, and wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl are each optionally substituted with amino or C 1-4 alkoxy.

2 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R a1 , R b1 , R c1 , and R d1 are each independently selected from H, 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C 1-6 alkyl, and (5-10 membered heteroaryl)-C 1-6 alkyl, wherein the 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C 1-6 alkyl, and (5-10 membered heteroaryl)-C 1-6 alkyl are each optionally substituted with 1 or 2 independently selected R 1A substituents; or

R c1 and R d1 , together with the nitrogen to which they are attached, come together to form a 10-14 membered heterocycloalkyl or 10-14 membered heteroaryl group.

3 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

each R 1A is independently selected from C 1-6 alkyl, C 3-10 cycloalkyl, 4-10 membered heterocycloalkyl, and CN, wherein each C 1-6 alkyl is optionally substituted with C 1-4 alkoxy.

4 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 2 is selected from H and C 1-6 alkoxy;

R 3 is selected from H, halo, and C 1-6 alkoxy;

R 4 is selected from H, 5-10 membered heteroaryl, CN, and C(O)NR c4 R d4 , wherein the 5-10 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 independently selected R 4A substituents;

R 5 is selected from H, halo, C 1-6 alkyl, and C 1-6 alkoxy; and

R 6 is selected from H and C 1-6 alkoxy.

5 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 4 and R 5 together with the carbon atoms to which they are attached, come together to form a 6-membered aryl ring which is optionally substituted with 1 or 2 independently selected R 7 substituents.

6 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

each R 7 is independently selected from C 3-10 cycloalkyl, 4-14 membered heterocycloalkyl, 5-10 membered heteroaryl, and OR a7 , wherein the C 3-10 cycloalkyl, 4-14 membered heterocycloalkyl, and 5-10 membered heteroaryl are each optionally substituted with 1 or 2 independently selected RA substituents.

7 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R a1 , R b1 , R c1 , and R d1 are each independently selected from H, 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C 1-6 alkyl, and (5-10 membered heteroaryl)-C 1-6 alkyl, wherein the 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C 1-6 alkyl, and (5-10 membered heteroaryl)-C 1-6 alkyl are each optionally substituted with 1 or 2 independently selected R 1A substituents;

or R c1 and R d1 , together with the nitrogen to which they are attached, come together to form a 10-14 membered heterocycloalkyl or 10-14 membered heteroaryl group;

each R 1A is independently selected from C 1-6 alkyl, C 3-10 cycloalkyl, 4-10 membered heterocycloalkyl, and CN, wherein each C 1-6 alkyl is optionally substituted with C 1-4 alkoxy;

R 2 is H or C 1-6 alkoxy;

U is CR 3 or N;

U′ is CR 5 or N;

U″ is CR 6 or N;

R 3 is selected from H, halo, and C 1-6 alkoxy;

R 4 is selected from H, 5-10 membered heteroaryl, CN, and C(O)NR c4 R d4 , wherein the 5-10 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 independently selected R 4A substituents;

R c4 and R d4 are each independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl;

each R 4A is an independently selected C 1-6 alkyl group;

R 5 is selected from H, halo, C 1-6 alkyl, and C 1-6 alkoxy;

or R 4 and R 5 together with the carbon atoms to which they are attached, come together to form a 5-6 membered aryl ring which is optionally substituted with 1, 2, 3, or 4 independently selected R 7 substituents;

R 6 is selected from H and C 1-6 alkoxy;

each R 7 is independently selected from C 3-10 cycloalkyl, 4-14 membered heterocycloalkyl, 5-10 membered heteroaryl, and OR a7 , wherein the C 3-10 cycloalkyl, 4-14 membered heterocycloalkyl, and 5-10 membered heteroaryl are each optionally substituted with 1 or 2 independently selected R 7A substituents;

each R a7 is an independently selected 4-10 membered heterocycloalkyl group; and

each R 7A is independently selected from C 1-6 alkyl, amino, C 3-6 cyclopropyl and 4-6 membered heterocycloalkyl, wherein each C 1-6 alkyl is optionally substituted with amino or C 1-4 alkoxy.

8 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R a1 , R b1 , R c1 , and R d1 are each independently selected from H, 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C 1-6 alkyl, and (5-10 membered heteroaryl)-C 1-6 alkyl, wherein the 4-10 membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-C 1-6 alkyl, and (5-10 membered heteroaryl)-C 1-6 alkyl are each optionally substituted with 1 or 2 independently selected R 1A substituents;

or R c1 and R d1 , together with the nitrogen to which they are attached, come together to form a 10-14 membered heterocycloalkyl or 10-14 membered heteroaryl group;

each R 1A is independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and CN, wherein each C 1-6 alkyl is optionally substituted with C 1-4 alkoxy;

R 2 is H or C 1-6 alkoxy;

U is CR 3 or N;

U′ is CR 5 or N;

U″ is CR 6 or N;

R 3 is selected from H, halo, and C 1-6 alkoxy;

R 4 is selected from H, 5-6 membered heteroaryl, CN, and C(O)NR c4 R d4 , wherein the 5-6 membered heteroaryl is optionally substituted with 1 or 2 independently selected R 4A substituents;

R c4 and R d4 are each independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl;

each R 4A is an independently selected C 1-6 alkyl group;

R 5 is selected from H, halo, C 1-6 alkyl, and C 1-6 alkoxy;

or R 4 and R 5 together with the carbon atoms to which they are attached, come together to form a 6-membered aryl ring which is optionally substituted with 1 or 2 independently selected R 7 substituents;

each R 7 is independently selected from C 3-10 cycloalkyl, 4-14 membered heterocycloalkyl, 5-10 membered heteroaryl, and OR a7 , wherein the C 3-10 cycloalkyl, 4-14 membered heterocycloalkyl, and 5-10 membered heteroaryl are each optionally substituted with 1 or 2 independently selected R 7A substituents;

each R a7 is an independently selected 4-10 membered heterocycloalkyl group; and each R 7A is independently selected from C 1-6 alkyl, amino, C 3-6 cyclopropyl and 4-6 membered heterocycloalkyl, wherein each C 1-6 alkyl is optionally substituted with amino or C 1-4 alkoxy.

9 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R a1 , R b1 , R c1 , and R d1 are each independently selected from H, methyl, pyrazolyl, pyridinylmethyl, pyridinylethyl, imidazo [1,2-a]pyridinylmethyl, benzoimidazolylmethyl, imidazo [4,5-c]pyridinylmethyl, benzoxazolylmethyl, oxetanylmethyl, oxetanylethyl, thietanyl-(1,1-dioxide) methyl, 2-oxaspiro [3.3]heptanyl, and 2-oxaspiro [3.5]nonanyl, wherein the methyl, pyrazolyl, pyridinylmethyl, pyridinylethyl, imidazo [1,2-a]pyridinylmethyl, benzoimidazolylmethyl, imidazo [4,5-c]pyridinylmethyl, benzoxazolylmethyl, oxetanylmethyl, oxetanylethyl, thietanyl-(1,1-dioxide) methyl, 2-oxaspiro [3.3]heptanyl, and 2-oxaspiro [3.5]nonanyl are each optionally substituted with 1 or 2 independently selected R 1A substituents;

or R c1 and R d1 , together with the nitrogen to which they are attached, come together to form 1,2,3,4-tetrahydrobenzo [4,5]imidazo [1,2-a] pyrazinyl;

each R 1A is independently selected from methyl, ethyl, methoxymethyl, and CN;

R 2 is H or C 1-6 alkoxy;

U is CR 3 or N;

U′ is CR 5 or N;

U″ is CR 6 or N;

R 3 is selected from H, halo, and C 1-6 alkoxy;

R 4 is selected from H, 5-6 membered heteroaryl, CN, and C(O)NR c4 R d4 , wherein the 5-6 membered heteroaryl is optionally substituted with 1 or 2 independently selected R 4A substituents;

R c4 and R d4 are each independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl;

each R 4A is an independently selected C 1-6 alkyl group;

R 5 is selected from H, halo, C 1-6 alkyl, and C 1-6 alkoxy;

or R 4 and R 5 together with the carbon atoms to which they are attached, come together to form a 6-membered aryl ring which is optionally substituted with 1 or 2 independently selected R 7 substituents;

each R 7 is independently selected from bicyclo[1.1.1]pentanyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, imidazolyl, azaspiro [3.3]heptanyl, diazaspiro [3.5]nonanyl, oxadiazaspiro[5.5]undecanyl, diazaspiro [4.4]nonanyl, and azetidinyloxy, wherein the bicyclo[1.1.1]pentanyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, imidazolyl, azaspiro [3.3]heptanyl, diazaspiro [3.5]nonanyl, oxadiazaspiro[5.5]undecanyl, and diazaspiro [4.4]nonanyl are each optionally substituted with 1 or 2 R 7A substituents; and each R 7A is independently selected from methyl, methoxyethyl, aminomethyl, amino, cyclopropyl, and oxetanyl.

10 . The compound of claim 1 , wherein the compound of Formula I is a compound of Formula II:

or a pharmaceutically acceptable salt thereof.

11 . The compound of claim 1 , wherein the compound of Formula I is a compound of Formula III:

or a pharmaceutically acceptable salt thereof.

12 . The compound of claim 1 , wherein the compound of Formula I is a compound of Formula IV:

or a pharmaceutically acceptable salt thereof.

13 . The compound of claim 1 , wherein the compound of Formula I is a compound of Formula V:

or a pharmaceutically acceptable salt thereof.

14 . The compound of claim 1 , which is selected from:

or a pharmaceutically acceptable salt thereof.

15 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

16 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

17 . A method of inhibiting an activity of a salt inducible kinase (SIK), the method comprising contacting the salt inducible kinase (SIK) with a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

18 . A compound, which is selected from:

or a pharmaceutically acceptable salt thereof.

19 . A pharmaceutical composition comprising a compound of claim 18 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20 . A method of inhibiting an activity of a salt inducible kinase (SIK), the method comprising contacting the salt inducible kinase (SIK) with a compound of claim 18 , or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2023
From: WEIN, MARC NATHAN; GREENLEE, WILLIAM J.
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 062727/0854 →
Continuity (2)
Provisional Application 63061515 · Aug 5, 2020
Related Publication 20240025892A1 · Jan 25, 2024
References Cited (75)
US 5990146A · Boschelli et al. · 1999 [cited by applicant]
US 6162804A · Bilodeau et al. · 2000 [cited by applicant]
US 6218388B1 · Boschelli et al. · 2001 [cited by applicant]
US 6380203B1 · Bilodeau et al. · 2002 [cited by applicant]
US 7071337B2 · Kath · 2006 [cited by examiner]
US 11998540B2 · Liau · 2024 [cited by examiner]
US 20040053942A1 · Alberti et al. · 2004 [cited by applicant]
US 20050124599A1 · Kath et al. · 2005 [cited by applicant]
US 20050176753A1 · Bilodeau et al. · 2005 [cited by applicant]
US 20100016353A1 · Henne et al. · 2010 [cited by applicant]
US 20100144751A1 · Marmsater et al. · 2010 [cited by applicant]
US 20130165652A1 · Gwak et al. · 2013 [cited by applicant]
CN 106565704A · 2017 [cited by applicant]
CN 107382983 · 2017 [cited by applicant]
CN 111433200 · 2020 [cited by applicant]
CN 115197208 · 2022 [cited by applicant]
CN 115448881 · 2022 [cited by applicant]
EP 1235825 · 2002 [cited by applicant]
EP 2931722 · 2015 [cited by applicant]
JP 2002501532A · 2002 [cited by applicant]
JP 2002523459A · 2002 [cited by applicant]
JP 2005530745A · 2005 [cited by applicant]
JP 2006501309A · 2006 [cited by applicant]
JP 2008515872A · 2008 [cited by applicant]
WO WO2003048132A1 · 2003 [cited by applicant]
WO WO2004113322 · 2004 [cited by applicant]
WO WO2008078091A1 · 2008 [cited by applicant]
WO WO2008121687A2 · 2008 [cited by applicant]
WO WO2008124323A1 · 2008 [cited by applicant]
WO WO2018136634A1 · 2018 [cited by applicant]
WO WO2019081353A1 · 2019 [cited by applicant]
WO WO2019105886 · 2019 [cited by applicant]
WO WO2019155456 · 2019 [cited by applicant]
WO WO2019238424 · 2019 [cited by applicant]
WO WO2020239658 · 2020 [cited by applicant]
WO WO2020239660 · 2020 [cited by applicant]
WO WO2022165529 · 2022 [cited by applicant]
WO WO2022165530 · 2022 [cited by applicant]
Xi et al. CAS: 159:577130, 2013. [cited by examiner]
Barth et al. CAS: 135: 33479, 2001. [cited by examiner]
Ardura et al., “Handling Parathormone Receptor Type 1 in Skeletal Diseases: Realities and Expectations of Abaloparatide,” Trends Endocrinol. Metab., Oct. 2019, 30(10):756-766. [cited by applicant]
Arjun et al., “Design, Synthesis, and Biological Evaluation of (E)-N′4(1-Chloro-3,4-Dihydronaphthalen-2-y1)Methylene)Benzohydrazide Derivatives as Anti-prostate Cancer Agents,” Frontiers in Chemistry, Jul. 2019, 7(474):… [cited by applicant]
Compston et al., “Osteoporosis,” Lancet, Jan. 2019, 393(10169):364-376. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2021/044673, mailed Feb. 16, 2023, 12 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2021/044673, mailed Nov. 23, 2021, 15 pages. [cited by applicant]
Jagerschmidt et al., “Abstract 1015: Preclinical Investigation of the First-in-Class SIK2/SIK3 Inhibitor GLPG3970 in Models of Arthritis,” Abstract, Presented at Proceedings of the ACR Convergence 2021, Virtual, Nov. 8,… [cited by applicant]
Maxfield et al., “SIK2 Restricts Autophagic Flux to Support Triple-Negative Breast Cancer Survival,” Mol. Cell Biol., Mar. 2016, 36(24):3048-3057. [cited by applicant]
Miranda et al., “Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche,” Cancer Cell, Aug. 2016, 30(2):273-289. [cited by applicant]
Mujahid et al., “A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin,” Cell Reports, Jun. 2017, 19(11):2177-2184. [cited by applicant]
Nishimori et al., “Salt-inducible kinases dictate parathyroid hormone 1 receptor action in bone development and remodeling,” J Clin. Invest., Aug. 2019, 129(12):5187-5203. [cited by applicant]
Pubchem SID No. 370057738, “3-Phenylpyrazolo[1,5-a]pyrimidine-6-carboxamid,” available May 25, 2018, retrieved on Oct. 19, 2021, 5 pages. [cited by applicant]
Sakamoto et al., “The Salt-Inducible Kinases: Emerging Metabolic Regulators,” Trends Endocrinol. Metab., Dec. 2018, 29(12):827-840. [cited by applicant]
Sato et al., “A FAK/HDAC5 signaling axis controls osteocyte mechanotransduction,” Nature Communications, Jul. 2020, 11(1):3282, 18 pages. [cited by applicant]
Sundberg et al., “Development of Chemical Probes for Investigation of Salt-Inducible Kinase Function in Vivo,” ACS Chemical Biology, Aug. 2016, 11(8):2105-11, 17 pages. [cited by applicant]
Tarumoto et al., “LKB1, Salt-Inducible Kinases, and MEF2C are Linked Dependencies in Acute Myeloid Leukemia,” Molecular Cell, Mar. 2018, 69(6):1017-1027.e6. [cited by applicant]
Tarumoto et al., “Salt-inducible kinase inhibition suppresses acute myeloid leukemia progression in vivo,” Blood, Jan. 2020, 135(1):56-70. [cited by applicant]
Wang et al., “Design, Synthesis and Biological Evaluation of Benzohydrazide Derivatives Containing Dihydropyrazoles as Potential EGFR Kinase Inhibitors,” Molecules, Aug. 2016, 21(8):1021, 21 pages. [cited by applicant]
Wein et al., “HDAC5 Controls MEF2C-Driven Sclerostin Expression in Osteocytes,” Journal of Bone and Mineral Research, Mar. 2015, 30(3):400-11. [cited by applicant]
Wein et al., “Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential,” Trends Endocrinol Metab., Oct. 2018, 29(10):723-735, 13 pages. [cited by applicant]
Wein et al., “SIKs control osteocyte responses to parathyroid hormone,” Nature Communications, Oct. 2016, 7:13176, 19 pages. [cited by applicant]
Zhou et al., “A novel compound ARN-3236 inhibits salt-inducible kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel,” Clinical Cancer Research, Apr. 2017, 23(8):1945-1954. [cited by applicant]
Klaeger et al., “The target landscape of clinical kinase drugs,” Science, Dec. 2017, 358(6367):eaan4368, 18 pages. [cited by applicant]
Office Action in Chinese Appln. No. 202180057654.6, dated Aug. 15, 2024, 20 pages (with English translation). [cited by applicant]
Partial European Search Report in European Appln. No. 21853415.4, dated Aug. 14, 2024, 18 pages. [cited by applicant]
Office Action in Chinese Appln. No. 202180057654.6, dated Mar. 22, 2024, 27 pages (with English translation). [cited by applicant]
Frett et al., “Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors,” HHS Public Access Author Manuscript, doi: 10.1016/j.ejmech.2015.02.052, publishe… [cited by applicant]
Search Report and Written Opinion in Singaporean Appln. No. 11202300456V, mailed on Nov. 26, 2024, 12 pages. [cited by applicant]
Office Action in Chinese Appln. No. 202180057654.6, mailed on Apr. 18, 2025, 11 pages (with English translation). [cited by applicant]
Extended European Search Report in European Appln. No. 21853415.4, mailed on Nov. 5, 2024, 16 pages. [cited by applicant]
Office Action in Chinese Appln. No. 202180057654.6, mailed on Feb. 6, 2025, 16 pages (with English translation). [cited by applicant]
Office Action in Japanese Appln. No. 2023-507619, mailed on Mar. 11, 2025, 4 pages (with English translation). [cited by applicant]
Office Action in Japanese Appln. No. 2023-507619, mailed on Aug. 5, 2025, 15 pages (with English translation). [cited by applicant]
SID 370057738, “3-Phenylpyrazolo[1,5-a]pyrimidine-6-carboxamide,” PubChem available May 25, 2025, retrieved on Aug. 13, 2025, retrieved from URL <https://pubchem.ncbi.nlm.nih.gov/substance/370057738>, 5 pages. [cited by applicant]
Extended European Search Report in European Appln. No. 25182598.0, mailed on Nov. 7, 2025, 12 pages. [cited by applicant]
Hicken et al., “Discovery of a novel class of imidazo [1, 2-a] pyridines with potent PDGFR activity and oral bioavailability,” ACS Medicinal Chemistry Letters, Nov. 2013, 5(1):78-83. [cited by applicant]